---
audienceLevel: patient
cancerTypes:
- lung
- pancreatic
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Zenocutuzumab-zbco - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/zenocutuzumab-zbco
version: v1
---

# Zenocutuzumab-zbco - NCI

# Zenocutuzumab-zbco

Placeholder slot

(ZEH-noh-kyoo-TOO-zyoo-mab)

This page contains brief information about zenocutuzumab-zbco and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Bizengri

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a33e782-fc75-4dba-b77c-a44536ac13a5&audience=consumer)

## Use in Cancer

Zenocutuzumab-zbco
is approved to treat adults with cancer that has an *NRG1* [gene fusion](/Common/PopUps/popDefinition.aspx?id=613509&version=Patient&language=English), has spread or cannot be removed by surgery, and has gotten worse during or after [systemic therapy](/Common/PopUps/popDefinition.aspx?id=45922&version=Patient&language=English), including:

- **[non-small cell lung cancer](/Common/PopUps/popDefinition.aspx?id=45323&version=Patient&language=English)**
- **[pancreatic adenocarcinoma](/Common/PopUps/popDefinition.aspx?id=44521&version=Patient&language=English)**

These uses are approved under [FDAâ€™s Accelerated Approval Program](https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval). As a condition of approval, a [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that zenocutuzumab-zbco provides a clinical benefit in these patients.

Zenocutuzumab-zbco
is also being studied in the treatment of other types of
cancer.

## More About Zenocutuzumab-zbco

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/794043) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Zenocutuzumab-zbco](https://medlineplus.gov/druginfo/meds/a625011.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Zenocutuzumab Approved to Treat Lung and Pancreatic Cancers with Rare Genetic Change](https://www.cancer.gov/news-events/cancer-currents-blog/2025/fda-zenocutuzumab-lung-and-pancreatic-cancers-nrg1-alteration)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Zenocutuzumab-zbco](https://www.cancer.gov/research/participate/clinical-trials/intervention/C152948) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
